AXIS Medical Education

Improving Outcomes and Addressing Racial Disparities in Patients With HR+/ HER2- Early Breast Cancer:

A Case-Based Learning Lab

This transcript has been edited for style and clarity and includes all slides from the presentation.



Provided by

AXIS Medical Education

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Improving Outcomes and Addressing Racial Disparities in Patients With HR+/ HER2- Early Breast Cancer: A Case-Based Learning Lab

Sara Tolaney, MD, MPH



Dr. Tolaney:
Hello and welcome to this educational activity.

My name is Sarah Tolaney. I am Chief of the Division of Breast Oncology and Associate Director of the Susan Smith Center for Women's Cancers at Dana-Farber Cancer Institute, and also Associate Professor of Medicine at Harvard Medical School. Today we'll be reviewing a patient case study to discuss the application and selection of CDK4/6 inhibitors for high-risk hormone receptor positive early breast cancer patients. So, let's go ahead and dive in and begin.

Case Study Patient Presentation and History

- A 48-year-old premenopausal Black woman palpated a mass in her right breast
- Imaging revealed a 3.5 cm mass
- Biopsy demonstrated a grade 2 invasive lobular carcinoma, ER 95%, PR 95%, HER2 1+
- An enlarged node was noted on axillary ultrasound and FNA was positive for malignant cells
- She underwent upfront surgery and was found to have a 4.1 cm grade 2 invasive lobular cancer, with 2/7 lymph nodes

AXIS Medical Education

ER, estrogen receptor; FNA, fine-needle aspiration; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.

So, this is a case of a 48-year-old premenopausal black woman who had palpated a mass in her right breast. She underwent imaging and was found to have a 3-and-a-half-centimeter mass and a biopsy of this area demonstrated a grade 2 invasive lobular carcinoma. It was estrogen receptor strongly positive at 95%, progesterone receptor positive also 95%, and HER2 was 1 plus. She also had an enlarged axillary node on the ipsilateral side and an axillary ultrasound was performed and an FNA was done of that lymph node, which was positive for malignant cells. She underwent upfront surgery and was found to have a 4.1-centimeter grade 2 invasive lobular carcinoma with 2 of 7 lymph nodes that were involved. So, this brings us to a question: What would be your next step for this patient?

Molecular Testing In Breast Cancer

- Biomarker testing for tumor ER, PR, and HER2 status is recommended for all patients
  - Ki-67 testing recently removed as a recommendation for HR+/HER2− patients who are being considered for abemaciclib
  - Methods for testing include: PCR, NGS, FISH, and IHC
- Genetic counseling and testing is recommended for patients considered to be at high risk for hereditary BC, who have TNBC, or who may be candidates for adjuvant olaparib
- Molecular profiling tests help to determine whether to add chemotherapy to ET for patients with HR+/HER2− eBC
- Gene expression assays critical in determining need for adjuvant chemotherapy:
  - The 21-gene assay (Oncotype Dx) is preferred by the NCCN for prognosis and prediction of chemotherapy benefit
  - Other prognostic assays: 70-gene (MammaPrint), 50-gene (Prosigna), 12-gene (EndoPredict), and Breast Cancer Index (BCI)

AXIS Medical Education

Gradishar WJ, et al. NCCN Guidelines. Breast Cancer. Version 2.2024. Markopoulos C, et al. *Eur J Surg Oncol.* 2020;46(4 Pt A):656-666. Blanchette P, et al. *Curr Oncol.* 2022;29(4):2599-2615.

BC, breast cancer; eBC, early breast cancer; ER, estrogen receptor; ET, endocrine therapy; FISH, flourescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; PCR, polymerase chain reaction; PR, progesterone receptor; TNBC, triple-negative breast cancer.

So certainly, there are lots of different tests we can consider in this setting. I think one of the tests that I think many of us would probably want to get in this setting is to get an Oncotype test in order to understand if this person would benefit from adjuvant systemic therapy. We do have data from the RxPONDER study in patients who did have 1 to 3 positive nodes and had hormone receptor-positive breast cancer that really showed us that, particularly in postmenopausal women, if you had a score of 25 or less, you really weren't benefiting from adjuvant chemotherapy. So, this to me is quite critical in patients who have early-stage breast cancer that is hormone receptor-positive for us to obtain in order to know who really needs chemotherapy.

There are also other biomarkers we could consider like Ki-67. This is really a marker trying to understand proliferation of the cancer, and there is data to suggest that having a higher Ki-67 is associated with higher risk of recurrence, so it is a prognostic marker. And while initially when we saw approval for a CDK4/6 inhibitor, it did come with needing to have a high Ki-67 for its indication. That has since been removed. So, in fact, one does not need to have information regarding Ki-67 to make a decision about use of adjuvant CDK4/6 inhibition. And so, in this particular patient, the thing that I would have really wanted to know would have been an Oncotype test to make sure if I needed chemotherapy or not in that particular patient.

Discussion: Risk Assessment

- What factors increase her risk of recurrence?
  - Nodal positivity
  - Grade and stage of disease
  - Positive margins
  - High proliferation rate
  - Younger age
  - HR and HER2 status
- High risk of recurrence based on:
  - Extent of nodal involvement
  - Tumor size
  - Tumor grade



▶ When thinking about risk in this patient, I think there are lots of factors that we have to consider. One is nodal positivity. We certainly know that the more lymph nodes that someone has involved, is associated with a higher risk of recurrence. The other thing we do consider, that is an independent prognostic indicator, is grade. So, particularly having a high-grade tumor, so grade 3 cancers, are also associated with higher risk of recurrence. The third important factor in my mind is tumor size. So again, the larger the tumor, the higher the risk. So, I think the 3 major points that I carry in my head when just looking at clinical anatomic information is grade, size, and nodal involvement.

There's certainly lots of other factors that are associated with higher risk – being of younger age, having positive margins – those are things that we also certainly take into account. And so, when we're making a decision in someone in the adjuvant setting who has early-stage hormone receptor-positive breast cancer, and we want to understand which patients could be candidates for abemaciclib, the major factors you have to think about are how many lymph nodes are involved. So, if someone has 4 or more positive lymph nodes, they are a candidate for abemaciclib. If they have 1 to 3 positive nodes, they are a candidate if they have a high-grade cancer or they have a tumor that is 5 centimeters or larger.

Risk of Early Breast Cancer Recurrence

Approximately 20-30% of patients with eBC experience relapse[1,2]

Factors that affect risk of recurrence in people with eBC[3-6]:

- Young age at diagnosis
- Tumor morphology (ductal versus lobular)
- Larger tumor size
- Higher tumor grade
- Symptomatic presentation
- Presence of lymphovascular invasion
- Axillary node involvement
- Negative ER or HER2 overexpression
- Positive or close margins
- PR negativity
- High proliferation rate (eg, high Ki-67)
- Metaplastic (vs. non-metaplastic) carcinoma

AXIS Medical Education

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). *Lancet*. 2005;365(9472):1687-1717. 2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). *Lancet*. 2015;386(10001):1341-1352. 3. Győrffy B, et al. *Breast Cancer Res*. 2015;17(1):11. 4. Dang CM, Giuliano AE. *Oncology (Williston Park)*. 2011;25(10):895-899. 5. Stuart-Harris R, et al. *Breast*. 2019;44:153-159. 6. Reddy TP, et al. *Breast Cancer Res*. 2020;22(1):121.
eBC, early breast cancer; ER, estrogen receptor; PR, progesterone receptor.

So unfortunately, approximately 20 to 30% of all patients who have early breast cancer will experience a relapse. And when we're trying to understand what are the factors that are associated with higher risk or recurrence, we've already mentioned that clinically, anatomic risk is something we do need to factor in. So, we need to know grade, nodal status, tumor size. But there are also other factors that we can consider. So, being of younger age is associated with higher risk of recurrence, having PR negativity, having higher proliferation scores, having evidence of lymphovascular invasion. And then, certain subtypes of breast cancer, for example, also are associated with higher risk, such as metaplastic carcinomas.



So, all of these things, again, come into play when trying to understand risk for an individual patient. And so, when we turn back to our particular patient, this patient did end up getting an Oncotype DX score and it did come back at 11. And so, if we remember from our data from RxPONDER that patients who had scores under 25 generally did not benefit from chemotherapy. However, there was data to suggest that pre-menopausal patients still were deriving some benefit from chemotherapy, and that benefit, again, was seen across scores that were less than 25. And so, it does make it complex when making a decision for a premenopausal patient, but I think in this case, because the patient had a lobular carcinoma and had a particularly low Oncotype DX, so coming back at 11, and discussing preferences with the patient, obviously very critical. And this patient was trying to avoid chemotherapy and so she elected not to get adjuvant chemotherapy and wanted to focus on maximizing endocrine therapy. So, in this case, went on to get ovarian suppression and an aromatase inhibitor. So, very critical in these cases where the decision is not so clear in my mind, when someone's premenopausal and has a recurrence score under 25, about whether or not we really need the chemotherapy or not, to really make a shared decision with your patient to really make sure that the patient's values are getting factored into this decision.

So, now the question is, if this patient has gone on to ovarian suppression and aromatase inhibitor, would you add a CDK4/6 inhibitor? And, if you do decide to use a CDK4/6 inhibitor, which one would you use?



So, when we think back to CDK4/6 inhibition and remember how these agents actually work, CDK4/6 in the pathway of breast cancer works by phosphorylating the retinoblastoma protein. This causes release of E2F, and then this causes a transition in the cell cycle from the G1 to S phase. So really, this is keeping the cell cycle going. But if you inhibit CDK4/6, in essence you halt the cell cycle at that G1/S transition point, and you put the cell into a senescent state. And there's some thought that this senescence can lead to eventual apoptosis.



And so, there are 3 different CDK4/6 inhibitors that are approved in the metastatic setting: palbociclib, abemaciclib, and ribociclib. But at this point, right now, we have approval just for abemaciclib in the early disease setting, but I think we anticipate that ribociclib should soon be approved. There have been many studies that have tried to look at adding a CDK4/6 inhibitor in the adjuvant space. Some of the first studies that were done actually looked at adding palbociclib to endocrine therapy in the early disease setting. So, there were 2 studies that looked at palbociclib. Unfortunately, both of these studies were negative trials, meaning that adding palbociclib to endocrine therapy did not improve long-term outcomes. However, we have seen two other trials that have been positive.



- The first of these is the monarchE study. This trial specifically looked at giving 2 years of adjuvant abemaciclib and adding it to endocrine therapy in patients with high-risk hormone receptor-positive breast cancer. And so, high-risk was defined as having 4 or more positive nodes, or if 1 to 3 positive nodes, either being high grade, or having a tumor that was greater than or equal to 5 centimeters. There was also a second cohort, though, for patients who had 1 to 3 positive nodes but didn't meet the grade or size criteria in cohort 1, and they instead met eligibility because they had a high Ki-67, so they were 1 to 3 positive nodes and high Ki-67, but tumor was under 5 centimeters, and it was not high grade. And so, there were about 5,600 patients that were randomized to get endocrine therapy with or without abemaciclib. And again, the abemaciclib was given for 2 years.



- And what we saw was that the 2 years of abemaciclib has led to a significant reduction in invasive disease-free survival events. And in fact, there is now 5 years of follow up from this trial, and at this point, what we've seen is almost a third reduction in events looking specifically at IDFS events. So, the hazard ratio was 0.68, and the absolute difference between the arms was 7.6%. So, clearly a very significant reduction in rates of recurrence from using 2 years of adjuvant abemaciclib.

Guidelines Overview: Adjuvant Endocrine Therapy

- Adjuvant ET for 5 years results in a substantial reduction in the risk of local recurrence, contralateral BC, distant recurrence, and risk of death
- The addition of chemotherapy to adjuvant ET is recommended in certain patients with HR+/HER2- breast cancer based on recurrence risk (Oncotype Dx 21-gene assay)
  - Postmenopausal patients with pT1-3, and pN0 and pN1 (1-3 positive nodes) tumors and a risk score ≥26
  - Premenopausal patients with pN0 tumors and a risk score ≥26
  - Premenopausal patients with pT1-3 and pN1 (1-3 positive nodes) tumors and a risk score ≥26
- The NCCN recommends the addition of a CDK4/6 inhibitor, abemaciclib, to systemic adjuvant ET for certain HR+/HER2−, high-risk eBC patients
  - ≥4 positive lymph nodes (confirmed preoperatively and/or at surgery)
    or
  - 1-3 positive lymph nodes with either grade 3 disease or tumor size ≥ 5cm (on pre-operative imaging and/or at surgery)
- Select patients may also be eligible for adjuvant abemaciclib after preoperative systemic therapy

Pan H., et al. *N Engl J Med.* 2017;377(19):1836-1846. Sheffield KM, et al. *Future Oncol.* 2022;18(21):2667-2682. Johnston SRD, et al. *Lancet Oncol.* 2023;24(1):77-90.
Gradishar WJ, et al. NCCN Guidelines. Breast Cancer. Version 2.2024.
BC, breast cancer; CDK, cyclin-dependent kinase; eBC, early breast cancer; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NCCN, National Comprehensive Cancer Network.

Case Study Clinical Course

- You explain to the patient that adding a CDK 4/6 inhibitor to hormone therapy can reduce her risk of recurrence vs hormone therapy alone by helping to kill cancer cells left behind after surgery, chemotherapy, or radiation
  - 35% reduction in the risk of cancer returning compared with hormone therapy alone
  - To prevent their cancer from progressing to incurable metastatic disease
- She was started on abemaciclib
  - For the treatment of HR+, HER2–, node-positive high-risk early breast cancer, NCCN® recommends considering the addition of 2 years of abemaciclib + ET as a Category 1 treatment option
  - High risk defined as ≥4 positive lymph nodes, or 1-3 positive lymph nodes with one or more of the following: grade 3 disease, tumor size ≥5cm

ET, endocrine therapy; NCCN, National Comprehensive Cancer Network®

- And so, at this point, the recommendation from multiple different guidelines is to consider abemaciclib in this high-risk population as defined by monarchE. So again, those patients who have 4 more positive nodes, or had 1 to 3 positive nodes and a tumor over 5 centimeters or was high-grade.

- So, if we circle back to our patient, again, remember this is a patient who has node-positive ER-positive lobular breast cancer, and she had elected not to get chemotherapy as a pre-menopausal woman with this Oncotype score of 11. And so, now you come back to thinking about whether or not you should add a CDK4/6 inhibitor. Remember, the patient had a tumor that at the time of surgery was actually 4.1 centimeters, was grade 2, and had 2 positive lymph nodes. So, technically not over 5 centimeters. Technically, not high grade. And this is someone with 1 to 3 positive nodes. So, this patient does fall just outside the monarchE eligibility. And so, I think it becomes a discussion about whether or not you think this patient should get abemaciclib. In my mind, this patient does have risk of recurrence because they have 2 positive nodes, they have a tumor that's almost 5 centimeters and its intermediate grade. And so, I would recommend abemaciclib in this particular patient, even though, again, they technically fell outside that monarchE eligibility. We saw that there was about a third risk reduction from the use of abemaciclib in this setting. This is also a patient who chose to forego adjuvant chemotherapy in a premenopausal population, and so I would be trying to maximize my endocrine therapy.

Discussion: Choosing a CDK 4/6 Inhibitor

When would you consider treatment with ribociclib?



- And so, then you think about, OK, well, if we are trying to maximize our adjuvant systemic treatment, how do we choose which CDK4/6 inhibitor to give? We just reviewed the data from monarchE and showed the benefits of abemaciclib in this setting, but there's also data now from NATALEE, which is a trial that looked at 3 years of adjuvant ribociclib. This trial was designed a little differently than monarchE because it took the standard dose that's used of ribociclib in the metastatic setting and reduced it. So, normally we give 600 milligrams of ribociclib for metastatic disease, this study used 400 milligrams in the adjuvant setting, and it also gave the ribociclib for 3 years. And remember, in monarchE the abemaciclib was for 2 years, so this is a longer duration of therapy. And the eligibility for the trial was broader than the eligibility in monarchE. So, you were eligible if you had any nodal involvement. So, 1 or more positive nodes automatically made you eligible, you didn't need another high-risk feature if you were node positive. But if you were node negative, you did need to have an additional high-risk feature. So, you needed to be at least 2 cm and have either a high Ki-67, or have a high genomic assay score, or be high grade. So, you needed to meet some other eligibility criteria in order to go on to the study if you were node negative.

NATALEE: Potential for Expanding Adjuvant CDK4/6i Use



Slide courtesy of Sara M. Tolaney, MD, MPH.|
Slamon DJ, et al. *Ther Adv Med Oncol.* 2023;15:17588359231178125.
CDK, cyclin-dependent kinase; N, node.

- So again, this is a broader number of patients than are in our monarchE because it's widening the eligibility to include, potentially, T2 and 0 patients and then, any nodal positive patient.

NATALEE: Invasive Disease–Free Survival



	RIB + NSAI	NSAI alone
Events/n (%)	226/2549 (8.9)	283/2552 (11.1)
3-Year iDFS rate, %	90.7	87.6
Hazard ratio (95% CI)	0.749 (0.628-0.892)	
Nominal 1-sided *P* value	.0006	

No. at risk										
RIB + NSAI	2549	2350	2273	2204	2100	1694	1111	368	21	0
NSAI alone	2552	2241	2169	2080	1975	1597	1067	354	26	0

- The median follow-up for iDFS was 33.3 months (maximum, 51 months)—an additional 5.6 months from the second interim efficacy analysis
- The absolute iDFS benefit with ribociclib plus NSAI was 3.1% at 3 years
- The risk of invasive disease was reduced by 25.1% with ribociclib plus NSAI vs NSAI alone

AXIS Medical Education

Hortobagyi G, et al. SABCS 2023. Abstract GS03-03; Slamon D, et al. ASCO 2023. Abstract LBA500.
iDFS, invasive disease-free survival; NSAI, nonsteroidal aromatase inhibitor; RIB, ribociclib.

- And we do have data now with 33 months of follow up that has suggested benefit from ribociclib with a hazard ratio of 0.75. So, about a 25% reduction in invasive disease-free survival events, which translated into a 3.1% absolute difference between the 2 arms. The challenge is the data is still early, because about 20% of patients are actually still getting their ribociclib on trial. So, we don't have data for after, when patients have completed their ribociclib, to see that that benefit has continued thereafter.

Case Study Clinical Course

- 8 days after starting abemaciclib, the patient developed diarrhea with up to 4 bowel movements per day

AXIS Medical Education

- So, in this particular case, given the longer follow-up time that we have from monarchE with greater maturity of data, it was elected for this patient to go on to abemaciclib. So, she went on to start her abemaciclib, but about 8 days later started experiencing diarrhea and she was having about four bowel movements a day. So, now what are you going to do?

Adverse Events Related to CDK4/6 Inhibitor Therapies and ET

- Ribociclib was associated with higher rates of hematological toxicity, primarily neutropenia, and liver—related adverse events
- Abemaciclib was associated with a high rate of gastrointestinal toxicities, primarily diarrhea (grade 1–2)
- Adjuvant abemaciclib has a tolerable safety profile with symptoms that are reversible and can be managed by dose reductions without compromising efficacy

Rastogi P, et al. *J Clin Oncol.* 2024;42(9):987-993.
CDK, cyclin-dependent kinase; ET, endocrine therapy.

- So, unfortunately, diarrhea is a pretty common side effect with abemaciclib. So, we see that about 80% of patients will have some level of diarrhea with abemaciclib, but it is mostly low-grade diarrhea. This is different than ribociclib, which doesn't carry with it the diarrhea, but instead, does have higher rates of hematologic toxicity with more neutropenia and more elevation of liver enzymes. So, the drugs do have different side-effect profiles.

monarchE: Safety Findings Consistent With Previous Analyses



Median duration of abemaciclib: 23.7 months

Other events of interest, any grade	Abemaciclib + ET N = 2791, %	ET Alone N = 2800, %
VTE	2.5	0.7
PE	1.0	0.1
ILD	3.3	1.3

Abemaciclib dose adjustments due to AEs
- Dose holds: 61.7%
- Dose reductions: 43.6%
- Discontinuations: 18.5% [8.9% after dose reduction]

All patients who received at least one dose of study treatment were included in the safety population. The safety profile of abemaciclib is considered manageable and acceptable for this high-risk population.

Johnston SRD, et al. SABCS 2022. Abstract GS1-09.
AE, adverse events; ET, endocrine therapy; ILD, interstitial lung disease; PE, pulmonary embolism; VTE, venous thromboembolism.

- If we dive in deeper in looking at the monarchE toxicity that was seen, again we mentioned that a little over 80% of people have some level of diarrhea, but only about 9% is high-grade diarrhea. The other rare side effects with abemaciclib to keep in mind are that you can see thromboembolic events. So, you can see about 2.5% of patients can develop a thromboembolic event while getting the abemaciclib endocrine therapy, and about 3% of patients can experience interstitial lung disease. And while these are very uncommon side effects, it's important to be aware of them. It's also important to be aware that the rate of thromboembolic events is higher if someone's taking abemaciclib concurrently with tamoxifen, where that rate is about 4%.

Abemaciclib Efficacy Is Not Compromised By Dose Reductions

Time dependent Cox model in patients treated with abemaciclib

Efficacy Endpoint	HR (95% CI) Staying at full dose vs Being reduced to lower doses
ITT	
iDFS	0.905 (0.727, 1.125)
DRFS	0.942 (0.742, 1.195)
Cohort 1	
iDFS	0.899 (0.718, 1.125)
DRFS	0.958 (0.750, 1.223)

Abemaciclib benefit was similar when given at the full dose of 150 mg compared to reduced doses of 100 mg or 50 mg

AXIS Medical Education

O'Shaughnessy J, et al. ESMO 2023. Abstract 274P.
DRFS, distant relapse-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intent-to-treat.

So, generally speaking, when someone is having diarrhea like this I would have held therapy. And the question then that comes up is, let's say, you held the therapy, the patient comes back and is doing much better, are you going to dose-modify them? And does dose modification actually carry with it some detriment to efficacy of the abemaciclib? I will say this is probably one of the most common questions my patients ask me is, I'm a little nervous if you reduce the dose, because they're worried that they're going to end up with a higher probability of recurrence and not gain as much benefit from the drug. But in fact, there has been data that has looked at the monarchE data and looked at those patients who had to have dose modifications and looked at efficacy and found no difference in efficacy, whether or not someone had lower dose exposure compared to those patients who maybe had higher dose exposure. And so, to me, this data was very reassuring because it told me that I should feel comfortable dose-modifying because it doesn't seem to impact outcomes here. So, normally with abemaciclib, you treat at 150 milligrams twice daily given on a continuous dosing schedule, but you can dose-modify down to 100 milligrams, or even down to 50 milligrams.

Monitoring and Managing Common Adverse Events

Diarrhea

- Take action immediately at the first signs of symptoms
  1. Start an over-the-counter anti-diarrheal and call your doctor
  2. Stay hydrated and drink clear fluids
  3. Watch for improvement and follow up with your doctor
- Dietary suggestions
  - Eat smaller meals more frequently
  - Choose foods that are easy to digest
    - Look for soft, bland foods
    - Eat foods that are high in sodium and potassium
  - Avoid:
    - Dairy products
    - High-fiber foods
    - Fatty or greasy foods
    - Spicy foods
    - Sugar-free candy or gum made with sugar alcohol
    - Food or drinks that have caffeine
    - Alcoholic drinks
    - Food or drinks that are too hot or too cold

Neutropenia and Liver Problems

- CBCs: Monitor complete blood counts prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated
- LFTs: Monitor ALT, AST, and serum bilirubin prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated

Generally managed by dose adjustments

AXIS Medical Education

VERZENIO (abemaciclib). Prescribing information. Eli Lilly and Company; 2024.
KISQALI (ribociclib). Prescribing information. Novartis; 2023.
ALT, alanine transaminase; AST, aspartate transaminase; CBC, complete blood count; LFT, liver function test.

So, in this patient who has diarrhea, again, always making sure when you educate someone prior to starting the abemaciclib that you make sure that they have loperamide on hand, that they are staying hydrated, that they're watching their diet because, certainly, some foods are associated with higher rates of diarrhea. So, important to educate people upfront about this and important to monitor patients. I do see patients back who are on abemaciclib every 2 weeks for the first 2 months, making sure that I'm checking their blood counts, as well as their liver enzymes. So, very important, again, to have this monitoring in place.



So, for this patient with the diarrhea, it is recommended to hold the abemaciclib, to use the antidiarrheal therapy like loperamide, as needed. And once the diarrhea is resolved, I would usually reinitiate the abemaciclib with dose-modification, usually going from that 150 dose down to 100 mg twice daily.



So, I think the other thing to keep in mind when caring for all our patients is trying to make sure that we address issues surrounding ethnic and racial disparities amongst our minority patients. We do know that being a black patient or of African ancestry is associated with higher rates of distant recurrence and has also been associated with delays in access to care. This is obviously very problematic, and we also know that a lot of our patients who do come from different racial and ethnic backgrounds can have lower rates of screening so sometimes cancers are found at a later stage. And this really, I think is something we need to do better with. And so, it is critical here that we are very good at engaging with our patients, that communication is good, and that education, in my mind, is key. So, for all of our patients we need to make sure that we're really explaining patients what their risk is upfront and making sure that we also explain why they're taking the medications that they're taking and give them potential strategies, also, to increase adherence. I think this really goes a long way with patients to help them understand what they're doing for treatment, and help them adhere to therapy along the way, and help them build more trust in our medical system So, in this particular case, again, a node positive patient who had hormone receptor-positive disease who had a low Oncotype score went on to get ovarian suppression, an AI, and abemaciclib. So, I think a very reasonable treatment approach to try to mitigate that risk of recurrence, but really important to be aware of potential toxicities and educate your patient upfront about them.



- When thinking about shared decision-making, it's really important to think about ways that we could do better in educating our patients. And there actually is a downloadable resource that is available to you to serve as a point-of-care reference and patient educational tool that I think will help facilitate providing equitable patient education, and really having a shared decision-making dialogue, so please do take advantage of it.



- Thank you so much for your attention.

REFERENCES

AHRQ. The SHARE Approach. https://www.ahrq.gov/health-literacy/professional-training/shared-decision/index.html

Blanchette P, Sivajohanathan D, Bartlett J, et al. Clinical utility of multigene profiling assays in early-stage invasive breast cancer: an Ontario Health (Cancer Care Ontario) clinical practice guideline. *Curr Oncol*. 2022;29(4):2599-2615.

Dang CM, Giuliano AE. Local recurrence risk factors in women treated with BCT for early-stage breast cancer. *Oncology (Williston Park)*. 2011;25(10):895-899.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. 2005;365(9472):1687-1717.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*. 2015;386(10001):1341-1352.

Gradishar WJ, Moran MS, Abraham J, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer (Version 2.2024). © 2024 National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the NCCN Guidelines®, go online to NCCN.org.

Győrffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L. Multigene prognostic tests in breast cancer: past, present, future. *Breast Cancer Res*. 2015;17(1):11.

Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. *Ann Oncol*. 2021;32(12):1571-1581.

Harbeck N, Rastogi P, O'Shaughnessy J, et al. Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Abstract presented at: European Society for Medical Oncology Congress; Madrid, Spain; October 20-24, 2023. Abstract LBA17.

Hortobagyi G, Stroyakovsky D, Yardley D, et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial. Abstract presented at: San Antonio Breast Cancer Symposium; San Antonio, Texas; December 5-9, 2023. Abstract GS03-03.

Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). *J Clin Oncol*. 2020;38(34):3987-3998.

Johnston SRD, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2023;24(1):77-90.

Johnston S, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. Abstract presented at: 2022 San Antonio Breast Cancer Symposium; San Antonio, TX; December 6-10, 2022. Abstract GS1-09.

KISQALI (ribociclib). Prescribing information. Novartis; 2023.

Loibl S, Marmé F, Martin M, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-The Penelope-B Trial. *J Clin Oncol*. 2021;39(14):1518-1530.

Markopoulos C, Hyams DM, Gomez HL, et al. Multigene assays in early breast cancer: insights from recent phase 3 studies. *Eur J Surg Oncol*. 2020;46(4 Pt A):656-666.

Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*. 2021;22(2):212-222.

O'Shaughnessy J, Cicin I, Testa L, et al. Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high risk early breast cancer (EBC): analyses from the monarchE study. Abstract presented at: European Society for Medical Oncology Congress; Madrid, Spain; October 20-24, 2023. Abstract 274P.

Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. *N Engl J Med*. 2017;377(19):1836-1846.

Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. *J Clin Oncol*. 2024;42(9):987-993.

Reddy TP, Rosato RR, Li X, Moulder S, Piwnica-Worms H, Chang JC. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. *Breast Cancer Res*. 2020;22(1):121.

Sheffield KM, Peachey JR, Method M, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. *Future Oncol*. 2022;18(21):2667-2682.

Slamon DJ, Fasching PA, Patel R, et al. NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC). *J Clin Oncol*. 2019;37(15_suppl):TPS597.

Slamon DJ, Fasching PA, Hurvitz S, et al. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. *Ther Adv Med Oncol*. 2023;15:17588359231178125.

Slamon D, Stroyakovskiy D, Yardley DA, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. Abstract presented at: American Society of Clinical Oncology Annual Meeting; Chicago, Illinois, June 2-6, 2023. Abstract LBA500.

Stuart-Harris R, Dahlstrom JE, Gupta R, Zhang Y, Craft P, Shadbolt B. Recurrence in early breast cancer: Analysis of data from 3,765 Australian women treated between 1997 and 2015. *Breast*. 2019;44:153-159.

VERZENIO (abemaciclib). Prescribing information. Eli Lilly and Company; 2024.

About AXIS Medical Education, Inc.

AXIS Medical Education, Inc. is a full-service continuing education company that designs and implements live, web-based, and print-based educational activities for healthcare professionals. AXIS provides convenient opportunities to engage learners based on their individual learning preferences through a full spectrum of educational offerings.

The executive leadership of AXIS combines 75 years of experience in adult learning theory, curriculum design/implementation/assessment, continuing education accreditation standards, and medical meeting planning and logistics. Our team has a deep understanding of the governing guidelines overseeing the medical education industry to ensure compliant delivery of all activities. AXIS employs an experienced team of medical and scientific experts, medical writers, project managers, meeting planners, and logistics professionals. This team is dedicated to meeting the unmet educational needs of healthcare professionals, with the goal of improving patient outcomes.

AXIS believes that partnerships are crucial in our mission to deliver timely, relevant, and high-quality medical education to healthcare professionals. To that end, AXIS partners with other organizations and accredited providers to offer added expertise and assist in expanding access to our educational interventions. AXIS also partners with numerous patient advocacy organizations to provide recommended patient education and caregiver resources in specific disease areas. AXIS finds value in these partnerships because they complement our core clinical curriculum with validated and relevant supplemental resources for busy clinicians and their patients.

The mission of AXIS is to enhance the knowledge, skills, competence, and performance of the interprofessional healthcare team to ensure patients receive quality care, resulting in improved patient outcomes. We engage healthcare professionals in fair-balanced, scientifically rigorous, expert-led certified educational activities designed to foster lifelong learning that is applicable to clinical practice and patient-centered care.

To learn more and to see our current educational offerings, visit us online at www.AXISMedEd.com.

AXIS Medical Education